相关实验视频

Updated: Jun 30, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

卵巢癌的基因组修饰相关的预后模型揭示了LBX2作为一种新的生长促进剂

Jian Xiong¹, Hongyuan Liang², Xiang Sun¹

¹Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

Journal of cellular and molecular medicine

|March 23, 2024

概括

基因基因基因基因可以预测卵巢癌 (OC) 的预后. 一个新的模型确定了五个关键基因,为新的OC疗法和诊断提供了潜力.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

卵巢癌 (OC) 存在重大挑战,治疗选择有限,生存率低.
质子修饰在癌症的发展和进展中起着至关重要的作用,但它们在OC中的预后价值需要进一步阐明.

研究的目的:

在卵巢癌中研究与基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因.
基于这些基因,开发OC患者预测结果的预测模型.
探索基因基因基因修饰基因,免疫透和OC中的治疗点之间的关系.

主要方法:

分析来自多个OC队列的大量和单细胞RNA测序数据.
基因组丰富分析以识别基因组修饰途径.
拉索回归用于识别差异表达基因 (DEG) 和构建预后模型.
在体外实验验验证基因表达模式和功能角色.

主要成果:

在OC中观察到色素修饰途径的丰富.
开发了一个五基因预后模型,证明了与免疫细胞透 (T细胞,M1巨细胞) 和突变流行率的相关性.
LBX2被确定为OC细胞增殖的新型促进剂.
对模型基因的药物查确定了潜在的治疗剂.

结论:

与基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因基因.
准这些基因可能为卵巢癌提供新的治疗策略.
作为OC进展中的潜在治疗点,LBX2值得进一步研究.

关键词:

在 LBX2 里.免疫透免疫透是什么?卵巢癌是发生在卵巢的癌症.预后预后预后它们的扩散和扩散.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...